Seres Therapeutics, Inc. (MCRB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1160468,
    "name": "Seres Therapeutics, Inc.",
    "stock_name": "Seres Therapeutics, Inc.",
    "full_name": "Seres Therapeutics, Inc.",
    "name_url": "stocks-analysis/seres-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "17.90",
    "chg": 1.2,
    "chgp": "7.19%",
    "dir": 1,
    "prev_price": "16.70",
    "mcapval": "200.04",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US81750R1023",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "232.05 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/seres-therapeutics-inc-1160468-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Seres Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-seres-therapeutics-inc-technically-bullish-or-bearish-3547367",
        "imagepath": "",
        "date": "2025-09-20 19:53:43",
        "description": "As of 19 August 2025, the technical trend for Seres Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish on the weekly and mildly bullish on the monthly. The KST shows a bullish trend weekly and mildly bullish monthly, while the OBV is mildly bearish weekly but mildly bullish monthly. \n\nIn terms of returns, the stock has outperformed the S&P 500 over the past week with a return of 2.62% compared to the S&P 500's 1.05%, but it has underperformed over the past month, year-to-date, and year. Overall, the current technical stance is bullish, driven primarily by the positive signals from MACD and moving averages...."
      },
      {
        "title": "Is Seres Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-seres-therapeutics-inc-overvalued-or-undervalued-3543760",
        "imagepath": "",
        "date": "2025-09-20 18:27:55",
        "description": "As of 8 July 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its current financial metrics, particularly with a Price to Book Value of 1.42 and an EV to Capital Employed ratio of 22.07, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the negative ROCE of -11917.50% and ROE of -132.49% highlight the company's struggles in generating returns for shareholders.\n\nIn comparison to its peers, Seres Therapeutics has a less favorable valuation profile, with Terns Pharmaceuticals, Inc. showing a more negative P/E of -6.9440 and Humacyte, Inc. at -1.8479, indicating that these companies are also facing challenges but are priced lower relative to their earnings potential. Over the past year, Seres Therapeutics has..."
      }
    ],
    "total": 7,
    "sid": "1160468",
    "stock_news_url": "https://www.marketsmojo.com/news/seres-therapeutics-inc-1160468"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Seres Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:53:43

As of 19 August 2025, the technical trend for Seres Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish on the weekly and mildly bullish on the monthly. The KST shows a bullish trend weekly and mildly bullish monthly, while the OBV is mildly bearish weekly but mildly bullish monthly. In terms of returns, the stock has outperformed the S&P 500 over the past week with a return of 2.62% compared to the S&P 500's 1.05%, but it has underperformed over the past month, year-to-date, and year. Overall, the current technical stance is bullish, driven primarily by the positive signals from MACD and moving averages....

Is Seres Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:27:55

As of 8 July 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its current financial metrics, particularly with a Price to Book Value of 1.42 and an EV to Capital Employed ratio of 22.07, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the negative ROCE of -11917.50% and ROE of -132.49% highlight the company's struggles in generating returns for shareholders. In comparison to its peers, Seres Therapeutics has a less favorable valuation profile, with Terns Pharmaceuticals, Inc. showing a more negative P/E of -6.9440 and Humacyte, Inc. at -1.8479, indicating that these companies are also facing challenges but are priced lower relative to their earnings potential. Over the past year, Seres Therapeutics has...

View All News